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The objective of this study was to describe human papillomavirus (HPV) prevalence in South Wales in relation to age, cytology and
social deprivation. This was an unlinked, prospective, anonymous, population-based study. DNA was purified from 1911 liquid-based
cytology samples (mean age 37.7 years, cytology 93.2% negative, social deprivation average score 17.9) using quality assured
techniques and the presence of virus determined by PCR-Enzyme Immuno Assay (PCR-EIA). 209 (10.9%) samples contained high-
risk (HR) HPV infection of which 36.4% had multiple HR-HPV types. The most frequent HR types were HPV 16 (19.6%), HPV 35
(9.5%), HPV 66 (9.2%), HPV 59 (8.5%) and HPV 56 (7.6%). There was a strong association between HPV infection and cytological
abnormality. Significantly more HR-HPV infections were detected in women under the age of 30 years (68.9% of all HR-HPV
infections Fisher’s exact test P¼0.0001) compared to 30 years and above. There was no difference in HPV prevalence between
different socioeconomic groups. The data presented suggest a different HPV type distribution in South Wales in comparison to that
reported for other populations.
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Cervical cancer is the second most prevalent female cancer
worldwide (Parkin et al, 2005). HR-human papillomavirus (HPV)
infection plays a central role in cervical carcinogenesis, with
HPV DNA identified in 99.7% of invasive cervical carcinomas
(Walboomerset al, 1999). However, HPV infection is common and in
the majority of cases self-limiting. An estimated 70% of infections
are transient and cleared within 18 months, with less than 1–2% of
high-risk infections resulting in cervical cancer. There is a large
discordance between the number of women infected (up to 80%
cumulative lifetime risk), and those who develop cervical cancer.
Further research is required to define prognostic biomarkers that
will identify women in whom HPV infection is likely to progress
to cervical neoplasia. Factors that may influence the outcome of
infection include HPV type, viral load and integration status.
The prevalence of HPV- and HPV-type-specific distribution
varies between different geographical regions worldwide (Clifford
et al, 2005a). HPV 16 and 18 are associated with an increased risk
of progression to cervical neoplasia (Clifford et al, 2003, 2005b).
However, the incidence of different HPV types in cervical cancers
has been found to vary with different geographical populations
(Bosch et al, 1995). Only a limited number of studies have
investigated HPV prevalence within the UK (Cuschieri et al, 2004;
Peto et al, 2004) with the results of the largest study to date
expected in November 2008 (Smyth et al, 2004).
HPV prevalence is age dependent with a peak in women below
the age of 25 (Schiffman et al, 1993; Petignat et al, 2005). In some
populations, however, a second peak in women over 55 has
been observed (Herrero et al, 2000; Molano et al, 2002). Social
deprivation has also been associated with cervical cancer
incidence, but the link is likely to be complex, as other factors
such as smoking, education and reduced participation in screening
must be considered (Sweetnam et al, 1981; Murphy et al, 1990; de
Sanjose et al, 1997; Krieger et al, 1999; Thomas et al, 2001; Parikh
et al, 2003; McFadden et al, 2004). However, not all studies have
been able to confirm this correlation (Parazzini et al, 1998).
Prophylactic HPV vaccines are currently in phase III trials and
should be available within 5 years. Prevalence studies are required
to identify baseline data against which efficacy of vaccination
can be compared, elucidate if type-replacement occurs following
vaccination and determine what fraction of disease is prevented.
Current vaccines only protect against HPV16 and 18 (Harper et al,
2004; Villa et al, 2005). Our laboratory has demonstrated that other
HPV types are linked with anogenital neoplasia in South Wales
(KW Hart, personal communication), underlining the need to
identify type-specific prevalence in this region.
Determination of HPV prevalence requires a nonselected
population, such as prospective sampling of screening groups,
although this will not capture those who fail to attend for
screening. When coverage by the screening programme is high,
sampling is likely to reflect the true prevalence of HPV infection
within a population. Studies of HPV infection with informed
consent may result in bias, as women may refuse testing or be
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sexcluded for logistical reasons. For these reasons prospective
anonymous sample collection was chosen to investigate HPV
prevalence within South Wales.
Here, we describe the first HPV prevalence study in Wales and
assess if there is an association between social deprivation, age or
cytology and HPV type.
MATERIALS AND METHODS
Clinical cohort
In total, 2023 consecutive screening samples were collected, with
the assistance of Cervical Screening Wales (CSW), over a 5-month
period in 2004. Cervical Screening Wales manages an organised
call–recall system inviting women aged 20–65 years for 3 yearly
cervical screening. The residual material of liquid-based cytology
(LBC) samples from women attending for routine cervical screen-
ing were used for this study. Inadequate cytology samples or those
from colposcopy clinics were excluded. This study was approved
by South East Wales Local Research Ethics Committee.
Sample processing
The LBC samples (Thinprep, Cytyc Corp, Boxborough, MA, USA)
were processed and analysed by the Cytology Laboratory at
Llandough Hospital, Cardiff, Wales. The residual specimen was
anonymised and transported to the HPV Laboratory, Wales
College of Medicine, Cardiff University. Samples were centrifuged,
washed with 10mM Tris-HCL (pH 7.4) and resuspended in 1ml
10mM Tris-HCL (pH 7.4) and stored at  801C until required for
further analysis.
DNA purification and PCR-EIA
Of 10mgml
 1 proteinase K (Boehringer Mannheim) 10ml was
added to a 100ml aliquot from each sample and incubated at 561C
for 2h, followed by 1001C for 10min. Samples were allowed to
cool, then centrifuged at 13000r.p.m. for 10min, and the
supernatant transfered to an appropriately labelled tube.
Standard HPV typing of LBC samples was performed using the
PCR-Enzyme Immuno Assay (PCR-EIA) method of Walboomers
et al (Jacobs et al, 1997) with minor modifications. PCR reac-
tions were performed in a final volume of 25ml and PCR cycling
conditions were 941C – 4min, then 40 cycles of 941C – 30s,
401C – 90s, 721C – 60s followed by 721C – 4min. Positive (CaSki)
and negative (water) PCR/ELISA controls were included in every
experiment, as were positive and negative DNA extraction
controls. A standard PCR for the house-keeping gene b-globin
was also performed on each sample to ensure PCR viability. 10% of
samples analysed were repeated to determine reproducibility.
Selection criteria for samples included in analysis
Detailed analysis was only performed on samples that conformed
to the following criteria:
1. b-Globin PCR positive (96% extraction efficiency)
2. Complete information available on age, cytology and social
deprivation score
3. Within the target screening age group 20–65 years
This eliminated 112 of the original 2023 samples. Detailed
analysis was performed on the remaining 1911 samples.
Cytology results
Cytology results were reported according to the guidelines of the
British Society of Cervical Cytology (BSCC) by the laboratory at
Llandough working within the CSW programme.
Age standardisation
The HR-HPV prevalence was age-standardised using the European
Standard Population (Waterhouse, 2003) and the following age-
standardised rate calculation:
X
Siria=
X
Si
where Si is the standard population sizes in the relevant age groups
and ‘i’ and ‘ria’ are the age-specific rates in age groups i and area
a (Breslow and Day, 1987).
Social deprivation score
Social deprivation was estimated by linking postcodes to the Welsh
Index of Multiple Deprivation (WIMD) (http://www.wales.gov.uk/
keypubstatisticsforwales/wimd2005.htm). WIMD is a Welsh As-
sembly Government funded project, developed to describe levels
of deprivation across Wales and support policy development and
the targeting of resources. The index provides an estimate of social
deprivation based on income, employment, health, education,
housing, access to services and physical environment. Each area
within Wales has been ranked according to social deprivation
score; rank 1 being the most deprived area with the highest social
deprivation score (78.9); the mid-range rank having a score of 17.9
and the lowest rank a social deprivation score of 1.4.
RESULTS
Study population
Of the 1911 samples included in the analysis, the mean age was 37.
7 years with 31.3% aged between 20–29 years, 26.4% 30–39 years,
22.2% 40–49 years, 14.9% 50–59 years and 5.2% over 60 years old.
In all, 93% were cytology negative, 3.9% had borderline changes
and 1.7, 0.4 and 0.7% had mild, moderate and severe dyskaryosis,
respectively. Figure 1 illustrates the distribution of samples
according to social deprivation score with 39.4% between 0–9.9,
32% 10–19.9, 10.8% 20–29.9, 6.6% 30–39.9, 4.7% 40–49.9, 4.6%
50–59.9 and 1.9% over 60. Thus, the majority of our sample
population is from areas not suffering notable deprivation.
HPV typing
317 HR-HPV infections were identified in 209 samples and an
additional 83 LR-HPV infections found. Of the 209 HR-HPV
positive samples, 114 were single infections, 59 were multiple
infections of HR types and 36 were multiple infections with both
LR and HR-HPV. There were 47 samples with single LR-HPV
infections. In total, 256 HPV infected samples were identified in
the 1911 samples included in the analysis, giving an overall HPV
prevalence for either HR or LR HPV of 13.4% (95% CI 11.9–15%).
The age standardised HR-HPV prevalence in the Welsh population
was 14.6%.
The distribution of HPV types is illustrated in Figure 2. The
distribution of specific HR-HPV types (n¼317) was as follows:
HPV 16 (19.6%), HPV 35 (9.5%), HPV 66 (9.2%), HPV 59 (8.5%),
HPV 56 (7.6%), HPV 58 (7.6%), HPV 18 (7.6%), HPV 31 (6.9%),
HPV 45 (5.4%), HPV 39 (5.1%), HPV 33 (4.7%), HPV 52 (4.1%),
HPV 51 (4.1%) and HPV 68 (0.3%).
Repeat experiments to validate the reproducibility of our results
identified 96% consistency in HR-HPV detection and 92% in
HR-HPV typing.
HPV prevalence and cytology
Comparison of cytological grades in the whole data set (n¼1911)
with those in the HR-HPV positive samples (n¼209) (Figure 3A
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sand B, respectively) reveals a significant decrease in the number of
cytology negative samples (93–59%) and an increase in borderline,
mild, moderate and severe cytology cases in the HR-HPV positive
samples. There was a marked increase in HPV prevalence with the
degree of dyskarosis detected from 6.9% in cytology negative
samples up to 92.9% in samples with severe dyskaryosis (Figure 4).
A breakdown of the incidence of specific HPV types in relation
to cytological grade (Figure 5) identifies HPV 16, HPV 35, HPV 39
and HPV 58 as more prevalent in dyskaryotic cells, with HPV 39
showing significantly higher incidence in dyskarotic than negative
samples (Fisher’s exact test P¼0.0112).
Negative and borderline cytology samples had a similar percentage
of single (4 and 23%, respectively) and multiple (2.2 and 25.7%,
respectively) HR-HPV infections. In dyskaryotic samples multiple
HR-HPV infections were more prevalent in mild (42.4%) than in
those with a moderate (12.5%) and severe cytological grading
(21.4%), whereas single HR-HPV infections were predominant in the
moderate (75%) and severe (57.1%) dyskarotic samples compared
with those observed in the mild (33.3%).
HPV prevalence and age
In all, 68.9% of HR-HPV and 64% of LR-HPV infections were found
in women aged under 30 years of age. The percentage of HR-HPV
infections observed within each age group decreased progressively
from 28% among 20–24 year olds, to 3% in those aged 45–49 years
with between 0.6 and 2% positive in women aged 50 and 65 years
(Figure 6). 75% of multiple HPV infections observed were in women
under 30 years old. Women aged between 50 and 59 years had a
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Figure 1 Distribution of samples according to social deprivation score (2005). The number of samples in each social deprivation score grouping from
0–9.9 to 70–79.9 in the total 1911 samples analysed.
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Figure 2 HPV type distribution in the Welsh population. The distribution of HR-HPV types and LR-HPV as a percentage of the total number of HPV
infections observed in this sample set (n¼400).
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Figure 3 Comparison of Cytological Grades. (A) The number of
samples in each cytology grade as a percentage of the total 1911 samples
analysed. (B) The number of HR-HPV samples in each cytology grade as a
percentage of the 209 HR-HPV samples identified.
HPV Prevalence in South Wales, UK
S Hibbitts et al
228
British Journal of Cancer (2006) 95(2), 226–232 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
shigher percentage of LR-HPV infections than HR-HPV infections
with 1.9 and 1.6% LR-HPV in women 50–54 years and 55–59 years,
respectively compared to 0.6 and 0.8% HR-HPV although not
statistically significant (Fisher’s exact test P¼0.4000).
HPV prevalence and social deprivation score
No correlation between HR-HPV prevalence and social deprivation
score was observed (Figure 7). The percentage of women with HR-
HPV infections when grouped according to social deprivation
score was between 7 and 15%.
DISCUSSION
Overview
The use of anonymous consecutive routine screening samples in this
study limits population bias with no women excluded. Collection of
the samples over a period of less than 6 months avoided testing of
the same subjects twice due to recall for repeat smears. The Welsh
population represents an ideal study cohort since it is demogra-
phically stable and socioeconomically well-defined.
HPV prevalence
Variability between HPV prevalence in different populations has
been highlighted in numerous studies but is complicated by
differences in study design, sample collection and methods used
for HPV detection and typing. A recent publication by Clifford
et al (2005a) reported data generated from the general populations
of 13 areas from 11 countries and identified large differences in
HPV prevalence in cytologically normal women ranging from 1.4%
in Spain up to 25.6% in Nigeria. There are currently relatively few
published HPV prevalence studies from the UK (Cuschieri et al,
2004; Peto et al, 2004) and even fewer reporting age-standardised
prevalence. In this cohort, we found an overall HPV prevalence of
13.4% with an age standardised HR-HPV prevalence of 14.6%. The
95% confidence interval of 11.9–15% indicates that this is likely to
be a reasonably accurate representation of HPV prevalence within
the 206369 women tested per annum by CSW from the Welsh
population. A direct comparison of this data with that obtained
from a Scottish cohort (Cuschieri et al, 2004) illustrates an overall
lower HPV prevalence in Wales than in Scotland (20.5% overall
and 15.17% HR-HPV in Scotland (not age-standardised)). How-
ever, within a European context, the HPV prevalence in Wales
would still be considered high, relative to prevalences of 8.8% in
Turin, Italy (Ronco et al, 2005) and 3.0% in Barcelona, Spain (de
Sanjose et al, 2003).
HPV 16, HPV 35, HPV 66 and HPV 59 were the most prevalent
HPV types in South Wales. However, comparison of our data with
the Scottish cohort identified an overall lower percentage of HPV
16, HPV 18, HPV 31, HPV 51, HPV 52 and HPV 68 and an increase
in HPV 35, HPV 66 and LR-HPV types. The high incidence of HPV
35 has been reported in other papers using the PCR-EIA method of
Walboomers et al. (Wall et al, 2005) and future work will
investigate this further.
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Figure 4 Percentage of HR-HPV positive in each cytology grade. The percentage ratio of HR-HPV samples to the total number of samples identified in
each cytology grade.
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Figure 5 HPV-type-specific distribution and cytology grade. The number of each HR-HPV type differentiated according to the cytology grades: negative,
borderline and dyskaryotic (mild, moderate and severe), calculated as a percentage of the total number of HR-HPV infections in each of these cytology grade
groups.
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Comparison of HR-HPV prevalence in relation to cytological grade
showed a strong association between HPV infection and cytolo-
gical abnormality (Figure 4). We also compared the distribution of
HR types among negative cytology samples with the distribution in
borderline and dyskaryotic samples (Figure 5); this indicated
that HPV 16, HPV 35, HPV 39 and HPV 58 were all over-
represented in dyskaryotic cytology samples relative to their
prevalence in borderline and negative cases and, in the case of
HPV 39, this was statistically significant. This raises the interesting
possibility that some types may be more strongly associated with
cellular dyskaryosis than others as previous studies have high-
lighted (Munoz et al, 2003). It will be interesting to see whether
such associations mirror the association of certain types (notably
HPV 16) with invasive disease. To gain a full understanding of the
relationships between HPV type, dyskaryosis and carcinoma,
further studies are required including an assessment of the specific
HPV types found in invasive carcinomas in the Welsh population.
HPV prevalence and age
HPV prevalence was highest in women aged 20–30 years. This is
consistent with other studies and is likely to be associated with a
higher number of recent sexual partners among this age group.
HR-HPV types were detected more frequently than LR-HPV types
in women aged 20–49 years and in all dyskaryotic cytology grades.
However, as reported in previous studies (Chan et al, 2002) a slight
increase in LR-HPV over HR-HPV was observed in women over 50
years old.
HPV prevalence and social deprivation score
There was no correlation between HR-HPV and social deprivation
score. However, it must be borne in mind that this study does not
provide a complete picture of social deprivation related to HPV
infection. This is because although use of a screening population
avoids many potential sources of bias, it inevitably only includes
people who attend for their smears. Hence, we do not have data on
the HPV status of nonattendees, and as this group has a higher
average social deprivation score than those who do attend for
smears, we cannot conclusively say that a correlation between HPV
infection and social deprivation does not exist (average social
deprivation score for women in this study¼17.9, average social
deprivation score for women not attending for smears in
2004¼21.9 indicating that nonattenders tend to reside in areas
of higher social deprivation (unpaired t-test Po0.0001)). It would
be interesting to study HPV infection in screening nonattendees
but such a study would be logistically problematic, although
possible using self-testing (Nobbenhuis et al, 2002).
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Figure 7 Percentage of women in each social deprivation score group infected with HR-HPV. The percentage ratio of HR-HPV samples to the total
number of samples identified in each social deprivation score group.
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Figure 6 Percentage of women in each age group infected with HR and LR-HPV. The percentage ratio of HR-HPV and LR-HPV samples to the total
number of samples identified in each age group.
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With prophylactic vaccination against HPV imminent, there is an
urgent need for accurate epidemiological studies to provide
baseline data, and so inform vaccine design regarding inclusion
of cohort-specific HPV types. Given the varying oncogenic
potential of different HPV types (Munoz et al, 2004), HPV type
prevalence is not the only factor influencing vaccine composition,
nonetheless, it is a significant factor. The data presented here
suggests that a vaccine purely based on HPV 16 and 18 may be less
effective in reducing cervical cancer incidence in the Welsh
population than in others.
CONCLUSION
In conclusion, HPV prevalence in South Wales is high, with HPV
16 and HPV 35 recognised as the two predominant circulating HR-
HPV types. Future work will aim to investigate a larger sample set
(n¼10000) to confirm HPV prevalence and the predominant HPV
types within South Wales.
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